Next, we assessed Rab25 expression in NSCLC patients who received EGFR‐TKI treatment and observed that patients with low Rab25 expression had a higher probability of responding to EGFR‐TKI therapy and better PFS and OS outcomes. Here, EGFR is linked to non-small cell lung carcinoma.